Clinical trial
Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer
NCT00095667 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00095667 |
|---|---|
| Title | Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer |
| Official title | A Phase 2 Study of GW572016 in Hormone Naive Recurrent or Metastatic Hormone Sensitive Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | lapatinib ditosylate, laboratory biomarker analysis |
| Enrollment | 41 |
| Start date | Nov 1, 2004 |
| Primary completion | Nov 1, 2007 |
| First posted | Nov 8, 2004 |
| Last update posted | May 8, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: